318 related articles for article (PubMed ID: 28315555)
1. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.
Gordon R; Kasler MK; Stasi K; Shames Y; Errante M; Ciccolini K; Skripnik Lucas A; Raasch P; Fischer-Cartlidge E
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):45-52. PubMed ID: 28315555
[TBL] [Abstract][Full Text] [Related]
2. Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
.
Mistry H; Forbes SG; Fowler N
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):53-59. PubMed ID: 28315558
[TBL] [Abstract][Full Text] [Related]
3. Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective.
Thebeau M; Rubin K; Hofmann M; Grimm J; Weinstein A; Choi JN
J Am Assoc Nurse Pract; 2017 May; 29(5):294-303. PubMed ID: 28436601
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
Davies M; Duffield E
Clin J Oncol Nurs; 2020 Jun; 24(3):277-283. PubMed ID: 32441679
[TBL] [Abstract][Full Text] [Related]
5. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
Vazquez A
Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
[TBL] [Abstract][Full Text] [Related]
6. Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice.
Bayer V; Amaya B; Baniewicz D; Callahan C; Marsh L; McCoy AS
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):13-21. PubMed ID: 28315552
[TBL] [Abstract][Full Text] [Related]
7. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
Davies M
Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
[TBL] [Abstract][Full Text] [Related]
8. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
Nagai H; Muto M
Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
[TBL] [Abstract][Full Text] [Related]
9. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
Champiat S; Lambotte O; Barreau E; Belkhir R; Berdelou A; Carbonnel F; Cauquil C; Chanson P; Collins M; Durrbach A; Ederhy S; Feuillet S; François H; Lazarovici J; Le Pavec J; De Martin E; Mateus C; Michot JM; Samuel D; Soria JC; Robert C; Eggermont A; Marabelle A
Ann Oncol; 2016 Apr; 27(4):559-74. PubMed ID: 26715621
[TBL] [Abstract][Full Text] [Related]
10. Update on New Therapies With Immune Checkpoint Inhibitors.
Peterson JJ; Steele-Moses SK
Clin J Oncol Nurs; 2016 Aug; 20(4):405-10. PubMed ID: 27441513
[TBL] [Abstract][Full Text] [Related]
11. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.
Ugolini H; Bryan J; Hennessy M; Kaufman HL; D'Angelo S
Clin J Oncol Nurs; 2019 Feb; 23(1):E1-E9. PubMed ID: 30682006
[TBL] [Abstract][Full Text] [Related]
12. Understanding Immune Checkpoint Inhibitors for Effective Patient Care.
Rubin KM
Clin J Oncol Nurs; 2015 Dec; 19(6):709-17. PubMed ID: 26583635
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy Summit: Proceedings and Identified Priorities for Safe Administration and Care.
Galioto M; Mucenski J
Clin J Oncol Nurs; 2019 Jun; 23(3):E60-E65. PubMed ID: 31099794
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
Kottschade LA
Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
16. The Future of Immunotherapy in the Treatment of Cancer.
Kottschade LA
Semin Oncol Nurs; 2019 Oct; 35(5):150934. PubMed ID: 31477413
[TBL] [Abstract][Full Text] [Related]
17. A large scale meta analysis identifies common adverse events with checkpoint inhibitors vs chemotherapy in melanoma patients.
Zhang R; Li X; You Z; Jiang L; Weng Y; Shi Q; Du L; Yan S
Int Immunopharmacol; 2019 Sep; 74():105691. PubMed ID: 31252248
[TBL] [Abstract][Full Text] [Related]
18. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
Bronstein Y; Ng CS; Hwu P; Hwu WJ
AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
[TBL] [Abstract][Full Text] [Related]
19. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
[TBL] [Abstract][Full Text] [Related]
20. [Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment].
Reinmuth N; Bitzer M; Deschler-Baier B; Fischer JR; Kuon J; Leipe J; Rawluk J; Schulz C; Heußel CP; Schultheiß M
Dtsch Med Wochenschr; 2019 Mar; 144(5):346-353. PubMed ID: 30699440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
